Abstract
ASD is a complex and common neurobehavioral disorder with no identified single specific biologic etiology. Instead there appear to be diverse abnormalities of brain networks with cellular, biochemical, and genetic factors. Though behavioral therapy is a major component to management of individuals with ASD, psychopharmacology has emerged as an important therapeutic tool. Pharmacology is targeted at associated disorders such as sleep disorders, aggression, anxiety, depression, repetitive behaviors, and hyperactivity. This chapter reviews current agents noted by research trials to be of benefit. Additional medications under current research are also briefly noted.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Association, Washington, DC
Anagnostou E, Soorya L, Chaplin W, Bartz J, Halpern D, Wasserman S, Wang AT, Pepa L, Tanel N, Kushki A, Hollander E (2012) Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 3:6–21
Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH (1984) Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141:1195–1202
Anderson IM, Kaczmarska J, McGrew S (2008) Melatonin for insomnia in children with autism spectrum disorders. J Child Neurol 23:482–485
Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, Ramadan Y (2006) Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 45:196–205
Antshel KM, Zhang-James Y, Faraone SV (2013) The comorbidity of ADHD and autism spectrum disorder. Expert Rev Neurother 13:1117–1128
Bullock TH, Bennett MVL, Johnston D, Josephson R, Marder E, Fields RD (2005) The neuron doctrine, redux. Science 310:791–793
Butler MG, Youngs EL, Roberts JL, Hellings JA (2012) Assessment and treatment in autism spectrum disorders: a focus on genetics and psychiatry. Autism Res Treat 2012:1–11
Bruni OMS (2007) Sleep in children with autism spectrum disorder. Sleep Med 9:64–70
Caccia S (2013) Safety and pharmacokinetics of atypical antipsychotics in children and adolescents. Paediatr Drugs 15:217–233
Campbell M, Anderson LT, Meier M, Cohen IL, Small AM, Samit C, Sachar EJ (1978) A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17:640–655
Campbell M, Armenteros J, Malone RP, Adams PB, Eisenberg ZW, Overall JE (1997) Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Assoc Psychiatry 36:835–843
Chhangani B, Greydanus DE, Patel DR, Feucht C (2011) Pharmacology of sleep disorders in children and adolescents. Pediatr Clin N Am 58:273–291
Cortesi F, Giannotti F, Ivanenko A, Johnson K (2010) Sleep in children with autism spectrum disorder. Sleep Med 11:659–664
Coury DL, Anagnostou E, Manning-Courtney P, Reynolds A, Cole L, McCoy R, Whitaker A, Perrin JM (2012) Use of psychotropic medication in children and adolescents with autism spectrum disorders. Pediatrics 130(Suppl 2):S69–76
Dove D, Warrant Z, McPheeters ML, Taylor JL, Sathe NA, Veenstra-VanderWeele J (2012) Medications for adolescents and young adults with autism spectrum disorders: a systematic review. Pediatrics 130:717–726
Doyle CA, McDougle CJ (2012) Pharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan. Dialogues Clin Neurosci 14:263–279
Eugene AL (2012) Children with hyperactivity & ASD research treatment study (CHARTS) consortium. Atomoxetine reduces ADHD symptoms in children with autism spectum disorder. Evid Based Ment Health 15:96–100
Farmer C, Thurm A, Grant P (2013) Pharmacotherapy for the core symptoms in autistic disorder: current status of research. Drugs 73:303–314
Fatemi SH, Realmuto GM, Khan L, Thuras P (1998) Fluoxetine in treatment of adolescent patients with autism: a longitudinal open trial. J Autism Dev Disord 28:303–307
Golubchik P, Sever J, Weizman A (2013) Reboxetine treatment for autistic spectrum disorder of pediatric patients with depressive and inattentive/hyperactive symptoms: an open-label trial. Clin Neuropharmacol 36:37–41
Greydanus DE, Pratt HD, Sloane MA, Rappley MD (2003) Attention-deficit/hyperactivity disorder in children and adolescents: interventions for a complex costly clinical conundrum. Pediatr Clin North Am 50:1049–1092
Greydanus DE, Pratt HD, Patel DR (2007) Attention deficit hyperactivity disorder across the lifespan. Dis Mon 53:65–132
Greydanus DE, Calles JL Jr, Patel DR (2008) Pediatric and adolescent psychopharmacology. Cambridge University Press, Cambridge, pp 199–222
Greydanus DE, Kaplan G, Antshel KM (2013) Attention deficit hyperactivity disorder: neuropsychologic and pharmacologic considerations. Int J Child Adolesc Health 6:22–30
Guy W (1976) ECDEU assessment manual for psychopharmacology. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, Washington, DC, pp 534–537
Handen BL, Johnson CR, Lubetsky M (2000) Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 30:245–255
Harfterkamp M, Buitelaar JK, Minderaa RB, van de Loo-Neus G, van der Gaag RJ, Hoekstra PJ (2013) Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study. J Child Adolesc Psychopharmacol 23:194–199
Healy A, Rush R, Ocain F (2011) Fragile X syndrome: an update on developing treatment modalities. ACS Chem Neurosci 17:402–410
Hosenbocus S, Chahai R (2013) Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 22:166–171
Hollander E, Phillips A, Chaplin W, Zagursky K, Novotny S, Wasserman S, Iyengar R (2005) A placebo controlled crossover trial of liquid fluoxetine on repetitive behaviors in childhood and adolescent autism. Neuropsychopharmacology 30:582–589
Hollander E, Soorya L, Wasserman S, Esposito K, Chaplin W, Anagnostou E (2006) Divalproex sodium vs placebo in the treatment of repetitive behaviors in autism spectrum disorder. Int J Neuropsychopharmacol 9:209–213
Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, Feirsen N, Pepa L, Anagnostou E (2010) Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorder Neuropsychopharmacology 35:990–998
Huerta M, Bishop Sl, Duncan A, Hus V, Lord C (2012) Application of DSM-5 criteria for autism spectrum disorder to three samples of children with DSM-IV diagnoses of pervasive developmental disorders. Am J Psychiatry 169:1056–1064
Ipser JC, Stein DJ, Hawkridge S, Hoppe L (2009) Pharmacotherapy for anxiety disorders in children and adolescents. Cochrane Database Syst Rev 8:CD005170
Jaselskis CA, Cook EH Jr, Fletcher KE, Leventhal BL (1992) Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322–327
Kaplan G (2012) Pharmacotherapy of adolescent ADHD. In: Greydanus DR, Patel DR, Omar HA, Feucht C, Merrick J (eds) Adolescent medicine: pharmacotherapeutics in general, mental, and sexual health. De Cruyter, Boston, pp 201–226.
Kaplan G (2013) What is new in adolescent psychiatry? A literature review and clinical implications. Adolesc Med State Art Rev 24:29–42
Kaplan G, McCracken JT (2012) Psychopharmacology of autism spectrum disorders. Pediatr Clin N Am 59:175–187
King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, Donnelly CL, Anagnostou E, Dukes K, Sullivan L, Hirtz D, Wagner A, Ritz L, STAART Psychopharmacology Network (2009) Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry 66:563–590
Kotagal S, Broomall E (2012) Sleep in children with autism spectrum disorder. Pediatr Neurol 47:242–251
Malone RP, Delaney MA, Hyman SB, Cater JR (2007) Ziprasidone in adolescents with autism: an open-label pilot study. J Child Adolesc Psychopharmacol 17:779–790
Mandell D, Morales K, Marcus SC, Stahmer AC, Doshi J, Polsky DE (2008) Psychotropic medication use among medicaid-enrolled children with autism spectrum disorders. Pediatrics 121:e441–448
Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG (2009) A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry 48:1110–1119
Martin A, Koenig K, Scahill L, Bregman J (1999) Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9:99–107
McCracken JT (2010) Disruptive behaviors. In: Hollander E, Kolevzon A, Coyle JT (eds) Autism spectrum disorders. American Psychiatric Publishing, Washington, DC, pp 159–167.
McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, Arnold LE, Lindsay R, Nash P, Hollway J, McDougle CJ, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez NM, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D, Research Units on Pediatric Psychopharmacology Autism Network (2002) Risperidone in children with autism and serious behavioral problems. N Engl J Med 347:314–321
McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH (1996) A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001–1008
McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, Arnold LE, Posey DJ, Martin A, Ghuman JK, Shah B, Chuang SZ, Swiezy NB, Gonzalez NM, Hollway J, Koenig K, McGough JJ, Ritz L, Vitiello B (2005) Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. Am J Psychiatry 162:1142–1148
Miano S, Ferri R (2010) Epidemiology and management of insomnia in children with autistic spectrum disorders. Paediatr Drugs 12:78–84
Murray MJ (2010) Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr Psychiatry Rep 12:282–288
Nazeer A (2011) Psychopharmacology of autistic spectrum disorders in children and adolescents. Pediatr Clin No Am 58:85–97
Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, Carson WH, Findling RL (2009) Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 124:1533–1540
Owley T, Walton L, Salt J, Guter SJ Jr, Winnega M, Leventhal BL, Cook EH Jr (2005) An open-label trial of escitalopram in pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 44:343–348
Paavonen EJ, Vehkalahi K, Vanhala R (2008) Sleep in children with Asperger syndrome. J Autism Dev Disord 38:41–51
Pardo CA, Buckley A, Thurm A, Lee LC, Azhagiri A, Neville DM, Swedo SE (2013) A pilot open-label trial of minocycline in patients with autism and regressive features. J Neurodev Disord 5:9
Parikh MS, Kolevzon A, Hollander E (2008) Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. J Child Adolesc Psychopharmacol 18:157–178
Paykina N, Greenhill L (2008) Attention deficit hyperactivity disorder. In: Findling RL (ed) Clinical manual of child and adolescent psychopharmacology. American Psychiatric Publishing, Washington, DC, pp 33–87
Politte LC, McDougle CJ (2014) Aytpical antipschotics in the treatment of children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 231:1023–1036
Posey DJ, Stigler KA, Erickson CA, McDougle CJ (2008) Antipsychotics in the treatment of autism. J Clin Invest 118:6–14
Potenza MN, Holmes JP, Kanes SJ, McDougle CJ (1999) Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19:37–44
Quintana H, Birmaher B, Stedge D, Lennon S, Freed J, Bridge J, Greenhill L (1995) Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 25:283–294
Richdale A (1999) Sleep problems in autism: prevalence, cause, and intervention. Dev Med Child Neurol 41:60–66
Robinson SJ (2012) Childhood epilepsy and autism spectrum disorders: psychiatric problems, phenotypic expression, and anticonvulsants. Neuropsychol Rev 22:271–279
Roke Y, Buitelaar JK, Boot AM, Tenback D, van Harten PN (2012) Risk of hyperprolactinemia and sexual side effects in males 10–20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. J Child Adolesc Psychopharmacol 22:432–439
Research Units on Pediatric Psychopharmacology Autism Network (RUPPa) (2005a) Risperidone treatment of autistic disorder: longer term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162:1361–1369
Research Units on Pediatric Psychopharmacology Autism Network (RUPPb) (2005b) Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders wtih hyperactivity. Arch Gen Psychiatry 62:1266–1274
Rush J, Nirenmberg A (2009) Mood disorders: treatment of depression. In: Sadock B, Sadock V, Ruiz P (eds) Kaplan and Sadock’s comprehensive textbook of psychiatry. Lippincott Williams & Wilkins, Philadelphia, pp 1734–1742
Scahill L, Aman MG, McDougle CJ, McCracken JT, Tierney E, Dziura J, Arnold LE, Posey D, Young C, Shah B, Ghuman J, Ritz L, Vitiello B (2006) A prospective open trial of guanfacine in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol 16:589–598
Schubart JR, Camacho F, Leslie D (2013) Psychotropic medication trends among children and adolescents with autism spectrum disorder in the medicaid program. Autism 18:631–637
Sharma A, Shaw S (2012) Efficacy of risperidone in managing maladaptive behaviors for children with autism spectrum disorder: a meta-analysis. J Ped Health Care 26:291–299
Siegel M (2012) Psychopharmacology of autism spectrum disorder: evidence and practice. Child Adolesc Psychiatr Clin N Am 21:957–973
Silver WG, Rapin I (2012) Neurobiological basis of autism. Pediatr Clin N Am 59:45–61
Tachibana M, Kagitani-Shimono K, Mohri I, Yamamoto T, Sanefuji W, Nakamura A, Oishi M, Kimura T, Onaka T, Ozono K, Taniike M (2013) Long-term administration of intranasal oxytocin is a safe and promising therapy for early adolescent boys with autism spectrum disorder. J Child Adolesc Psychopharmacol 23:123–127
Taurines R, Schwenck C, Westerwald E, Sachse M, Siniatchkin M, Freitag C (2012) ADHD and autism: differential diagnosis or overlapping traits? A selective review. Atten Defic Hyperact Disord 4:115–139
Tchaconas A, Adesman A (2013) Autistic spectrum disorders: a pediatric overview and update. Curr Opin Pediatr 25:130–144
Tuchman RF (2013) Deconstructing autism spectrum disorders: clinical perspective. Rev Neurol 56:S3–12
Tordjman S, Najjar I, Bellissant E, Anderson GM, Barburoth M, Cohen D, Jaafari N, Schischmanoff O, Fagard R, Lagdas E, Kermarrec S, Ribardiere S, Botbol M, Fougerou C, Bronsard G, Vernay-Leconte J (2013) Advances in the research of melatonin in autism spectrum disorders: literature review and new perspectives. Int J Mol Sci 14:20508–20542
Weblink #1 (2012) http://www.forbes.com/sites/emilywillingham/2012/10/11/new-dsm-5-criteria-for-autism-who-will-be-left-behind/
Weblink #4 (2012) http://www.clinicaltrials.gov/ct2/show/NCT01725152?term=ganaxolone&rank=3
Williams K, Wheeler DM, Silove N, Hazell P (2013) Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 8:CD004677
Young D, Nagarajan L, de Klerk N (2007) Sleep problems in Rett syndrome. Brain Dev 29:609–616
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Greydanus, D., Kaplan, G., Patel, D. (2015). Pharmacology of Autism Spectrum Disorder. In: Fatemi, S. (eds) The Molecular Basis of Autism. Contemporary Clinical Neuroscience. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2190-4_9
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2190-4_9
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2189-8
Online ISBN: 978-1-4939-2190-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)